Process Economic Drivers in Industrial Monoclonal Antibody Manufacture

[1]  R L Fahrner,et al.  Membrane ion-exchange chromatography for process-scale antibody purification. , 2001, Journal of chromatography. A.

[2]  Karol Lacki,et al.  Technical and economical evaluation of downstream processing options for monoclonal antibody (MAb) production , 2006 .

[3]  Wolf-Dieter Deckwer,et al.  Cost Comparison of Protein Capture from Cultivation Broths by Expanded and Packed Bed Adsorption , 2003 .

[4]  Geoffrey Hodge.  Disposable components enable a new approach to biopharmaceutical manufacturing , 2004 .

[5]  Brian Hubbard,et al.  Downstream processing of monoclonal antibodies--application of platform approaches. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  C. Schmelzer,et al.  Expanded bed adsorption in the purification of monoclonal antibodies: a comparison of process alternatives , 2001, Bioseparation.

[7]  G. Allard,et al.  Production of a diagnostic monoclonal antibody in perennial alfalfa plants. , 1999, Biotechnology and bioengineering.

[8]  Cristiana Boi,et al.  Membrane adsorbers as purification tools for monoclonal antibody purification. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  Jörg Thömmes,et al.  Alternatives to Chromatographic Separations , 2007, Biotechnology progress.

[10]  Anthony Clemento.  New and Integrated Approaches to Successful Accelerated Drug Development , 1999 .

[11]  T. Torphy,et al.  Monoclonal antibodies: boundless potential, daunting challenges , 2002 .

[12]  Joe X. Zhou,et al.  Basic Concepts in Q Membrane Chromatography for Large‐Scale Antibody Production , 2006, Biotechnology progress.

[13]  Keith L Carson.  Flexibility—the guiding principle for antibody manufacturing , 2005, Nature Biotechnology.

[14]  Brian Kelley,et al.  Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations , 2007, Biotechnology progress.

[15]  T. Bibila,et al.  In Pursuit of the Optimal Fed‐Batch Process for Monoclonal Antibody Production , 1995, Biotechnology progress.

[16]  A Sadana,et al.  Efficiency and economics of bioseparation: some case studies. , 1994, Bioseparation.

[17]  Yuhong Zhou,et al.  A Software Tool to Assist Business‐Process Decision‐Making in the Biopharmaceutical Industry , 2005, Biotechnology progress.

[18]  K. Thiel,et al.  Biomanufacturing, from bust to boom...to bubble? , 2004, Nature Biotechnology.

[19]  S Karri,et al.  A Tool for Modeling Strategic Decisions in Cell Culture Manufacturing , 2000, Biotechnology progress.

[20]  Yuhong Zhou,et al.  Application of a Decision‐Support Tool to Assess Pooling Strategies in Perfusion Culture Processes under Uncertainty , 2008, Biotechnology progress.

[21]  Suzanne Farid.  A decision-support tool for simulating the process and business perspectives of biopharmaceutical manufacture. , 2002 .

[22]  Jochen Strube,et al.  Challenges in biotechnology production—generic processes and process optimization for monoclonal antibodies , 2005 .

[23]  Suzanne S Farid,et al.  Process economics of industrial monoclonal antibody manufacture. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  S. Bhatia,et al.  The Road Ahead for Biologics Manufacturing , 2002 .

[25]  Deborah K Follman,et al.  Factorial screening of antibody purification processes using three chromatography steps without protein A. , 2004, Journal of chromatography. A.

[26]  Suzanne S. Farid,et al.  Integrated approach to improving the value potential of biopharmaceutical R&D portfolios while mitigating risk , 2006 .

[27]  Alexander Moscho,et al.  Deals that make sense , 2000, Nature Biotechnology.

[28]  Suzanne S Farid,et al.  A computer‐aided approach to compare the production economics of fed‐batch and perfusion culture under uncertainty , 2006, Biotechnology and bioengineering.

[29]  T. Przybycien,et al.  Alternative bioseparation operations: life beyond packed-bed chromatography. , 2004, Current opinion in biotechnology.

[30]  S. Nochumson,et al.  Rethinking the economics of chromatography: New technologies and hidden costs , 2003 .

[31]  Suzanne S Farid,et al.  Combining Multiple Quantitative and Qualitative Goals When Assessing Biomanufacturing Strategies under Uncertainty , 2008, Biotechnology progress.

[32]  J. Bonnerjea,et al.  Scale-up of monoclonal antibody purification processes. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  Carl-Gustaf Rosen,et al.  Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator , 1993, Bio/Technology.

[34]  Brian D Kelley.  Bioprocessing of therapeutic proteins , 2001 .

[35]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[36]  Anurag S. Rathore,et al.  Costin issues in the production of biopharmaceuticals: Manufacturing costs are crucial to overall profit margins , 2004 .

[37]  Suzanne S Farid,et al.  Established bioprocesses for producing antibodies as a basis for future planning. , 2006, Advances in biochemical engineering/biotechnology.

[38]  S. Chamow,et al.  Therapeutic antibody expression technology. , 2001, Current opinion in biotechnology.

[39]  Suzanne S Farid,et al.  Decision‐Support Tool for Assessing Biomanufacturing Strategies under Uncertainty: Stainless Steel versus Disposable Equipment for Clinical Trial Material Preparation , 2008, Biotechnology progress.

[40]  Sanchayita Ghose,et al.  Evaluation and comparison of alternatives to Protein A chromatography Mimetic and hydrophobic charge induction chromatographic stationary phases. , 2006, Journal of chromatography. A.

[41]  Duncan Low,et al.  Future of antibody purification. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[42]  R. Werner,et al.  Economic aspects of commercial manufacture of biopharmaceuticals. , 2004, Journal of biotechnology.

[43]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[44]  M. Kamarck,et al.  Building biomanufacturing capacity—the chapter and verse , 2006, Nature Biotechnology.